The pharmaceutical field is experiencing a major shift in blood sugar therapy with the arrival of GLP-1 transdermal devices. These groundbreaking methods offer a likely convenient option to subcutaneous injections for individuals managing type 2 diabetes. By circumventing the requirement for freq